PATIENT ALERT: Masks are now optional in our VOA offices. If you are immunocompromised or feeling ill, masking is strongly encouraged. CLICK HERE for more details​​​​​​.
CLICK HERE regarding the Change Healthcare update.

Clinical Research & Trials

uso 22326

CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

 

Disease Types: Breast Cancer Research

Eligibility Requirements:

-Women and Men, >18 years at the time of screening (or per national guidelines)                                                                                                                                                                              -Histologically confirmed ER+/HER2- early-stage resected invasive breast cancer with high or intermediate risk of recurrence, based on clinical-pathological risk features, as defined in the protocol.                                                                                                                                                                                                                                                                                                  -Completed adequate (definitive) locoregional therapy (surgery with or without radiotherapy) for the primary breast tumour(s), with or without (neo)adjuvant chemotherapy                                --Completed at least 2 years but no more than 5 years (+3 months) of adjuvant ET (+/- CDK4/6 inhibitor)                                                                                                                                          -Eastern Cooperative Oncology Group (ECOG) performance status of < 1                                                                                                                                                                                          -Adequate organ and marrow function

Available at: